RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 56-66
  • Raw deal for AbbVie, but does anyone care?

    Raw deal for AbbVie, but does anyone care?
    AbbVie got hosed on its aborted Shire deal. Let's get that up top. It's also very hard to feel sorry for it. Sure, the North Chicago-based pharmaceutical business failed to score Adderall and the Irish outfit behind it. You can make all the cracks you...
  • Abbott earnings tumble as costs offset better sales

    Abbott earnings tumble as costs offset better sales
    Abbott Laboratories on Wednesday said third-quarter earnings tumbled 44 percent on a tax charge that offset an uptick in sales. The north suburban-based maker of infant formula, medical devices and drugs, said it earned $538 million in the most recent...
  • Ebola scams spreading as fears mount

    Ebola scams spreading as fears mount
    I can't tell you whether to believe assurances from those in power that the deadly Ebola virus will be kept in check, but there's no doubt that panicking can expose you to harm. Scams related to the Ebola outbreak are spreading and you aren't immune....
  • AbbVie says tax rule changes scuttled deal for Shire

     AbbVie says tax rule changes scuttled deal for Shire
    AbbVie is blaming the Obama administration for pulling the plug on its $55 billion proposed acquisition of Irish drugmaker Shire, asserting that the largest corporate deal of the year no longer made economic sense under new federal tax regulations. Late...
  • AbbVie board calls off Shire acquisition

    AbbVie board calls off Shire acquisition
    North Chicago-based drugmaker AbbVie has pulled the plug on its plan to buy Dublin-based Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules. Shire stands to be paid a break-up fee of about $1.64...
  • Magnetic stimulation gains in depression treatment

     Magnetic stimulation gains in depression treatment
    A machine that sends magnetic pulses into a patient's brain has become the new frontier of depression treatment, promising to ease symptoms for those who have found little relief from medication or talk therapy. The treatment, known as transcranial...
  • AbbVie reconsiders its option with Shire

     AbbVie reconsiders its option with Shire
    AbbVie's surprise announcement late Tuesday that it is having second thoughts about its proposed acquisition of Shire raises numerous questions about the future of the deal. The North Chicago-based drugmaker said its board of directors will take...
  • As Rx deaths dip, heroin overdoses surge

    As Rx deaths dip, heroin overdoses surge
    Prescription drug deaths declined in 2012 for the first time in more than a decade, but a surge in fatal heroin overdoses wiped out the modest improvement, according to U.S. government statistics released Wednesday. Fatal heroin overdoses rose 35% to 5,...
  • How to judge Medicare plans

    How to judge Medicare plans
    While much of the nation is preoccupied with Obamacare and picking new health insurance at work, older Americans have deadlines of their own coming up — involving Medicare. We're just a few days away from the two-month period when the nation's...
  • Feds to publicize drug company payments to doctors

    Feds to publicize drug company payments to doctors
    For decades, Big Pharma and medical technology firms have made gifts and other payments to physicians as part of developing, testing and marketing their products, an expense long recognized as another cost of doing business. On Tuesday, the federal...
  • Why we allow Big Pharma to rip us off [Commentary]

    Why we allow Big Pharma to rip us off [Commentary]
    According to a new federal database put online last week, pharmaceutical companies and device makers paid doctors some $380 million in speaking and consulting fees over a five-month period in 2013. Some doctors received over $500,000 each, and some...